

Published: January 12, 2026, 7:45 pm

---

The [Guardian has reported](#) this morning that:

*People on weight loss drugs regain all the weight they have lost within a year of stopping the medication, analysis has shown.*

*Analysis of 11 studies of older and newer GLP-1 weight loss drugs by the University of Oxford found that patients typically lost 8kg on weight loss jabs but returned to their original weight within 10 months of stopping them.*

*The study, presented at the European Congress on Obesity, found that even for those taking newer, higher-dose weight loss drugs such as Wegovy and Mounjaro, people put weight back on once they stopped treatment.*

Why note this? That is because what this evidence makes very clear is what I have been suggesting on this blog for a while, and that is that the purpose of these drugs is not to solve the problem of obesity. It is instead intended to create a new form of dependency, or even addiction. In this case, this dependency is on the weight loss drugs that the person becomes totally reliant upon to maintain their body image, and so their mental health, whatever the physical health side effects might be (and they can be serious, with significant potential long-term costs to the NHS).

The serious medical side effects of these drugs are ignored by most of their users. They want the dopamine hit of being slimmer without having to adjust their lifestyles, or to address the other addictions that they must shake off if they are to achieve sustainable weight loss. Those addictions are most especially to sugar and carbohydrates.

The GLP-1 drug industry is not, I suggest, interested in the side effects of its drugs. These are, as far as it is concerned, an economic externality that they can ignore as someone else (the state) will bear that cost.

And they are definitely not interested in suggesting that the other addictions that those who become dependent on their drugs might have be addressed, because if they were, then the steady flow of new sugar and carbohydrate addicts on which their business model now depends will be impacted.

Most bizarrely, the NHS, whose job it should be to see through all this and rise above it, very clearly does not do so. It has been captured by commercial interests whose only interest is in promoting addiction or dependency, at the very least.

All the GLP-1 drugs have done is add another drug on which people can become dependent, quite possibly for life, to the vast array that the NHS already spends a fortune on to keep the medical-pharmaceutical industry in the extraordinary level of profits to which it has become accustomed, without ever actually solving almost any of our real health problems, to all of which it turns a blind eye, as to address them would reduce their future earnings.

There is a sickness at the heart of the NHS in the form of drug companies, who are fleecing us all.